Study details
Enrolling now
A Study of 19-28z/IL-18 in People With Acute Lymphoblastic Leukemia (ALL)
Memorial Sloan Kettering Cancer Center
NCT IDNCT06287528ClinicalTrials.gov data as of Apr 2026
Phase
Phase 1
Target enrollment
18
Study length
about 4 years
Ages
17+
Locations
7 sites in NJ, NY
About this study
This trial is testing a new treatment called 19-28z/IL-18 CAR T cells for people with acute lymphoblastic leukemia. Participants will have their white blood cells collected and modified to become this therapy, which takes about two to four weeks.
Based on ClinicalTrials.gov records.
What participants do
- 1.Receive 19-28z/IL-18 CAR T cells
PhasePhase 1
DrugIL-18 CAR T cells
Primary goalToxicity as determined by CTCAE, version 5.0
Participation effort
Estimated from trial records. Details can vary by site.
Time + visits
Low12%
Logistics
Moderate50%
Logistics difficulty varies by site location and availability.
Trial highlights
Treatment details
Auto-extracted from trial records to preview treatments and outcomes.
Drug classes
cell therapy (Engineered T-cells that target specific cancer antigens)
Endpoints
Primary: Toxicity as determined by CTCAE, version 5.0
Body systems
Oncology